GWM
IONS icon

Graybill Wealth Management’s Ionis Pharmaceuticals IONS Stock Holding History

Graybill Wealth Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-61,225
Closed -$3.78M – 51
2014
Q4 		$3.78M Sell
61,225
-29,015
-32% -$1.43M 2.87% 3
2014
Q3 		$3.5M Sell
90,240
-680
-0.7% -$24.1K 2.69% 7
2014
Q2 		$3.13M Buy
+90,920
New +$2.86M 2.42% 11

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Graybill Wealth Management's IONS Position: Q1 2015 in Review

Graybill Wealth Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2015, closing a stake of 61,225 shares — an estimated $3.78M sold.

Graybill Wealth Management first reported a position in IONS in Q2 2014 and held it in 3 quarters. The position peaked at $3.78M in Q4 2014. 339 funds tracked by Wall St. Rank hold IONS as of Q1 2015.

  • Graybill Wealth Management reported no remaining Ionis Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Graybill Wealth Management sold 61,225 Ionis Pharmaceuticals shares in Q1 2015, an estimated $3.78M.
  • Graybill Wealth Management first reported a position in Ionis Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Graybill Wealth Management's Ionis Pharmaceuticals position peaked at $3.78M in Q4 2014.
  • 339 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2015.

Based on Graybill Wealth Management's 13F filing for Q1 2015, filed 20 Apr 2015.